INSITE VISION RECEIVES SPECIAL PROTOCOL ASSESSMENT FROM A FDA FOR A DOUBLE PHASE 3 CLINICAL TRIAL OF AZASITE PLUS™ …

InSite Vision Receives Special Protocol Assessment from the FDA for the DOUBle Phase 3 Clinical Trial of AzaSite Plus™ …
InSite Vision Incorporated today voiced that the Company has reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the pattern of a Phase 3 clinical hearing of AzaSite Plus™ and DexaSite™ in patients with blepharitis.

Read more on Business Wire around Yahoo! Finance